started · updated
Huons Lab secures patents for HyDIFFUZE antibody subcutaneous compositions
Huons Lab, a subsidiary of Huons Global, has secured intellectual property rights for its HyDIFFUZE platform technology. The company announced the completion of domestic patent registrations and international patent applications (PCT) for 11 different antibody drug subcutaneous (SC) compositions.
HyDIFFUZE utilizes recombinant human hyaluronidase to temporarily break down hyaluronic acid in subcutaneous tissue, allowing drugs to disperse more widely and rapidly. Non-clinical pharmacokinetic (PK) evaluations demonstrated that the HyDIFFUZE-applied SC formulations achieved a maximum blood concentration (Cmax) between 113% and 170% higher, and drug exposure (AUC) between 117% and 162% higher, compared to SC formulations without the technology.
The 11 targeted antibody drugs include Pembrolizumab, Bevacizumab, Obinutuzumab, Ramucirumab, Donanemab, Isatuximab, Durvalumab, Dostarlimab, Cetuximab, Risankizumab, and Dupilumab. The company intends to expand the application of HyDIFFUZE to various biologics, including antibody-drug conjugates (ADCs).
Additionally, Huons Lab is currently undergoing review by the Ministry of Food and Drug Safety for its standalone recombinant human hyaluronidase product, following an application submitted last December.
Entities
Huons Global · Huons Lab · HyDIFFUZE · Ministry of Food and Drug Safety
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Huons Lab registered domestic patents and filed PCT applications for 11 antibody drug subcutaneous compositions using its HyDIFFUZE technology. www.bosa.co.kr · www.hin.company · kormedi.com
- [● 3 SOURCES] Non-clinical PK evaluations showed HyDIFFUZE-applied SC formulations achieved 113% to 170% higher Cmax compared to non-HyDIFFUZE SC formulations. www.bosa.co.kr · www.hin.company · kormedi.com
- [● 3 SOURCES] The 11 antibody drugs tested include Pembrolizumab, Bevacizumab, Obinutuzumab, Ramucirumab, Donanemab, Isatuximab, Durvalumab, Dostarlimab, Cetuximab, Risankizumab, and Dupilumab. www.bosa.co.kr · www.hin.company · kormedi.com
- [● 3 SOURCES] Huons Lab applied for MFDS approval for its standalone recombinant human hyaluronidase product in December last year. www.bosa.co.kr · www.hin.company · kormedi.com
- [● 3 SOURCES] Drug exposure (AUC) was 117% to 162% higher in the HyDIFFUZE-applied group compared to the group without HyDIFFUZE. www.bosa.co.kr · www.hin.company · kormedi.com